Case Studies

logo Lonza Lonza Biotec Czech Republic

Lonza Czech Republic, a subsidiary of the Swiss company Lonza, provides process-development services and established a facility in the Czech Republic in 1993.

  • total site area: 6.7 ha
  • employees: 395, 20% of whom are university graduates
  • production lines ranging from 15m3 to 75 m3 (total reactor volume: 475 m3)
  • most of the production output is exported (EU, US, Japan)
  • FDA approved, cGMP, HACCP, FAMI-QS and other standards
  • own R&D department

 ,, Lonza Kouřim is the leading technology and manufacturing service provider for biopharmaceuticals in Eastern Europe. “

  • Stephan Borgas, CEO of Lonza

 “The Czech Republic has a strong tradition in standard biotechnologies such as production of beer, alcohol, antibiotics, amino acids, vitamins and other products requiring special fermentationprocesses. Thanks to the rising quality of basic biological research and construction of new research centres with funding provided by the European structural funds, the development of the sector of top biotechnology companies focused on diagnostics and therapeutic media for human medicine can be expected.”

  • Peter Šebo, Institute of Biotechnology AS CR